Pharmacological Intervention to Modulate HDL: What Do We Target?

by Nicholas J. Woudberg, Sarah Pedretti, Sarah Pedretti, Sandrine Lecour, Rainer Schulz, Nicolas Vuilleumier, Richard W. James, Miguel A. Frias, Miguel A. Frias
Published 2018-01-01

HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3.

by Sarah Pedretti, Marie-Claude Brulhart-Meynet, Fabrizio Montecucco, Sandrine Lecour, Richard W James, Miguel A Frias
Published 2019-01-01

Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients

by Tafadzwa Chimbetete, Phuti Choshi, Sarah Pedretti, Mireille Porter, Riyaadh Roberts, Rannakoe Lehloenya, Rannakoe Lehloenya, Jonathan Peter, Jonathan Peter, Jonathan Peter
Published 2023-05-01

Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics

by Ana Copaescu, Phuti Choshi, Sarah Pedretti, Effie Mouhtouris, Jonathan Peter, Jonathan Peter, Jason A. Trubiano, Jason A. Trubiano, Jason A. Trubiano, Jason A. Trubiano
Published 2021-08-01

Corrigendum: Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics

by Ana Copaescu, Phuti Choshi, Sarah Pedretti, Effie Mouhtouris, Jonathan Peter, Jonathan Peter, Jason A. Trubiano, Jason A. Trubiano, Jason A. Trubiano, Jason A. Trubiano
Published 2021-09-01

Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury.

by Marie-Claude Brulhart-Meynet, Vincent Braunersreuther, Jonas Brinck, Fabrizio Montecucco, Jean-Christophe Prost, Aurelien Thomas, Katia Galan, Graziano Pelli, Sarah Pedretti, Nicolas Vuilleumier, François Mach, Sandrine Lecour, Richard W James, Miguel A Frias
Published 2015-01-01